European Medicines Agency gives XX opinion on Johnson & Johnson vaccine



The European Medicines Agency (EMA) issued its opinion on Tuesday April 20, 2021 on the Johnson & Johnson vaccine against Covid-19. – Allen J Schaben / Los Angeles Time / SIPA

The EMA opinion was eagerly awaited by pharmaceutical company Johnson & Johnson. The European Medicines Agency finally estimated on Tuesday that the benefit / risk balance of the American group’s vaccine against Covid-19 remained “positive”. This notice comes at the same time as vaccination is expanding to all citizens in the United States. For his part, White House medical adviser Anthony Fauci said Sunday that a decision in the United States should be made public by Friday.

The use of the Johnson & Johnson vaccine had previously been suspended in Europe and the United States due to the rare occurrence of serious blood clots in patients. The EMA ruled on Tuesday in its press release that blood clots should be added to the rare side effects. Several European countries, including France, are counting on this vaccine to speed up their immunization campaign.



Source link